Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Prostatype Genomics

0.56 SEK

-1.06 %

Less than 1K followers

PROGEN

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Compare
-1.06 %
-3.10 %
-1.40 %
-53.74 %
-90.66 %
-87.43 %
-99.45 %
-99.89 %
-99.85 %

Prostatype Genomics operates in the medical technology sector. The company specializes in the development of medical genetic tests used for the identification, analysis and further follow-up of prostate cancer. In addition to its main business, related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic market. The head office is located in Nacka Strand.

Read more
Market cap
33.26M SEK
Turnover
49.01K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
12.2.
2026

Annual report '25

All
Press releases
ShowingAll content types
Regulatory press release11/25/2025, 1:30 PM

Prostatype Genomics' Newsletter: Update on Medicare application and publication of U.S. study results

Prostatype Genomics
Press release11/19/2025, 7:06 AM

BioStock: Video from Prostatype Genomic's presentation at BioStock Life Science Summit 2025

Prostatype Genomics
Regulatory press release11/11/2025, 2:45 PM

Previous Investments in Research and Development Unlock Hidden Assets in Prostatype Genomics

Prostatype Genomics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Regulatory press release9/24/2025, 8:45 PM

New shares from exercise of warrants of series TO5 registered

Prostatype Genomics
Regulatory press release9/18/2025, 5:00 PM

Prostatype Genomics AB receives SEK 11.5 million in connection with warrants of series TO5

Prostatype Genomics
Regulatory press release9/12/2025, 7:05 AM

The last day of trading in Prostatype Genomics AB’s warrants of series TO5 is on Monday

Prostatype Genomics
Regulatory press release9/3/2025, 6:55 PM

Prostatype Genomics AB enters into pre-subscription and top-down underwriting commitments corresponding to 37.2 percent in ongoing warrant exercise

Prostatype Genomics
Regulatory press release9/3/2025, 6:45 AM

The exercise period for Prostatype Genomics AB’s warrants of series TO5 commences today

Prostatype Genomics
Regulatory press release9/2/2025, 6:45 AM

Prostatype Genomics AB announces fixed exercise price for warrants of series TO5

Prostatype Genomics
Press release8/28/2025, 2:00 PM

Update regarding Prostatype Genomics’ application to Medicare concerning reimbursement for Prostatype® in USA

Prostatype Genomics
Regulatory press release8/26/2025, 6:30 AM

Prostatype Genomics reaches important commercial breakthrough by initiating billing for Prostatype® to insurance companies in the USA

Prostatype Genomics
Regulatory press release8/7/2025, 6:15 PM

Prostatype Genomics AB changes Certified Adviser to Tapper Partners AB

Prostatype Genomics
Regulatory press release7/23/2025, 10:10 AM

Prostatype Genomics publishes its interim report for the first half of 2025

Prostatype Genomics
Press release7/22/2025, 12:05 PM

Positive results for Prostatype® confirmed in published Spanish multicentre study

Prostatype Genomics
Regulatory press release6/23/2025, 10:15 AM

Prostatype Genomics' Newsletter: Initiated clinical use at several U.S. top-ranked hospitals and urology clinics

Prostatype Genomics
Regulatory press release6/19/2025, 7:15 PM

Prostatype Genomics AB announces last day of trading in BTU and first day of trading in warrants of series TO5

Prostatype Genomics
Regulatory press release6/18/2025, 11:30 AM

Prostatype Genomics AB carries out directed issue of units to underwriters in recently completed rights issue

Prostatype Genomics
Regulatory press release6/5/2025, 8:20 PM

Prostatype Genomics AB’s rights issue of units fully subscribed

Prostatype Genomics
Regulatory press release6/3/2025, 7:00 AM

Strong results for Prostatype® in published Taiwan study – creating opportunities for commercial expansion in Asia

Prostatype Genomics
Press release6/2/2025, 6:45 AM

Prostatype Genomics engages Healthcare Capital Mergers as U.S. transaction advisor

Prostatype Genomics
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.